Oddo BHF raises target for Sartorius Stedim stock from EUR 239.00 to EUR 281.00

Sartorius Stedim Biotech (ISIN FR0013154002) was trading at EUR 215.60 at Lang & Schwarz on October 7, 2026 at 9:39 a.m. CEST, plus 0.40 percent versus the prior close of EUR 214.75. Ideal Investisseur reported that Oddo BHF raised its Sartorius Stedim target from EUR 239.00 to EUR 281.00 in a publication dated October 2, 2026.

Oddo BHF lifts the valuation bar

The new target lies 30.33 percent above the Lang & Schwarz price. Oddo BHF maintained an Outperform rating, while Goldman Sachs had raised its target from EUR 208.00 to EUR 223.00 one day earlier, according to Ideal Investisseur.

The figures show why valuation has become the central issue. The market price is below both analyst targets, but the latest target revisions also raise the hurdle for further gains because expectations already reflect a recovery in bioprocessing demand.

First-half results set the earnings frame

Ideal Investisseur reported first-half 2026 revenue of EUR 1.527 billion, EBITDA of EUR 463.70 million and an EBITDA margin of 31.40 percent. Net income for the same period was EUR 181.10 million.

The company also maintained its fiscal 2026 framework, with expected revenue of EUR 3.154 billion and EBITDA of EUR 989.20 million. The guidance gives investors a concrete benchmark: the full-year revenue target is more than double the first-half figure, while the projected EBITDA margin is approximately 31.37 percent when calculated from the two stated guidance values.

Stock remains close to yearly high

At EUR 215.60, Sartorius Stedim stock sits EUR 9.40 below its 52-week high of EUR 225.00 and EUR 65.60 above its 52-week low of EUR 150.00, based on the October 7, 2026 market snapshot. The market capitalization was EUR 21.1 billion on the same date.

Euronext identifies Sartorius Stedim Biotech as a Paris-listed supplier of equipment and services for biopharmaceutical development, quality assurance and production. Its listing and operating profile make the analyst targets a direct test of the expected recovery in customer investment.

Price holds above EUR 215.00

Sartorius Stedim Biotech was trading at EUR 215.60 at Lang & Schwarz on October 7, 2026 at 9:39 a.m. CEST, plus 0.40 percent versus the prior close of EUR 214.75. The reference price is EUR 9.40 below the 52-week high of EUR 225.00. The further course of trading is shown by the continuously updated real-time quote of Sartorius Stedim stock.

More news and analyses on Sartorius Stedim stock